Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of QHRD106 in Healthy Chinese Subjects
NCT06388772Phase 1Completed
- Sponsor
- Changzhou Qianhong Biopharma Co., Ltd.
- Start
- Jul 2021
- Primary completion
- Jul 2022
- Modality
- Recombinant Proteins and Enzymes, PEGylated Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in ischemic stroke comparing QHRD106 (SAD Cohorts) with Placebo (2 arms). Primary endpoints: Incidence, severity, and causality of adverse events and Plasma measurements of QHRD106. Started Jul 2021; status: completed.
02
Drugs
QHRD106
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT06388772.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06388772.